Colorectal cancer – A silent killer

Colorectal cancer awareness month
It's important to detect and screen for colorectal cancer at early stage. With newer therapies and drugs, colorectal cancer can be treated at early stage.

Share This Post

Colorectal cancer, a type of cancer that can remain silent, can have no symptoms at an early stage, but it is the third leading cause of cancer-related deaths in the United States. March is colorectal cancer month, do you have enough knowledge about colorectal cancer?

Colorectal cancer does not have any symptoms in the early stage, and once found, most of them are in advanced stage. However, screening can help detect cancer early, and may involve stool tests, colonoscopy, or other surgeries. Non-risk ordinary people should also start colorectal cancer screening at the age of 50, but people with higher risk factors, such as Crohn’s disease history, inflammatory bowel disease, or those with certain genetic markers, should start screening earlier check. Although colorectal cancer kills about 50,000 Americans each year, you can still reduce your risk of cancer. Increasing physical activity, limiting alcohol intake, and avoiding smoking have been shown to completely reduce the risk of colorectal cancer. 

Colorectal cancer is highly treatable, and the earlier it is detected, the greater the chance of survival. So, don’t ignore screening. This colorectal cancer month, should you do something?

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy